Home » Newsletters » BioWorld Science

BioWorld Science

July 31, 2009

View Archived Issues

RheothRx now in development for pain in sickle cell crisis

Vanguard Medica antimigraine drug in phase II

Eisai Alzheimer's drug in advanced development

Transcend's procysteine progresses in the clinic

GlaxoSmithKline presents second quarter 2009 results

Delcath Systems updates clinical progress with melphalan and its PHP drug delivery system

Mologen to include additional dosing group in phase Ib/IIa study of MGN-1703

Immunomedics and Alexis sign partnership agreement for vaccines against cancer and AIDS

Can-Fite licenses allosteric modulators from Leiden University and the NIH

Avi and Action Duchenne collaborate for Duchenne muscular dystrophy treatment

SUVN-502 shown to be safe and well tolerated in phase I trial in healthy subjects

CAD-106 is safe and immunogenic in first-in-man trial in AD patients

S1P1 receptor agonists claimed by Arena for inflammatory and autoimmune diseases

Genentech claims MEK kinase inhibitors for cancer treatment

Novel mu-opioid receptor ligands discovered at NeuroSearch

Bayer Schering Pharma claims PPARalpha ligands for the treatment of dyslipidemia

GlaxoSmithKline discovers CGRP antagonists for the treatment of migraine

Cell Therapeutics initiates marketing approval process for pixantrone in Europe

Evotec receives milestone payment from collaboration with Boehringer Ingelheim

European Commission approves broader label for Avastin in breast cancer

Foresight initiates FST-100 trial in viral conjunctivitis

NHLBI stops clinical trial of sildenafil for PH in sickle cell disease

MVI and Crucell form partenership to accelerate development of malaria vaccine

AstraZeneca to initiate phase IIb study of CytoFab for severe sepsis

Cardium presents update on phase IIb MATRIX study of Excellarate in diabetic ulcers

Merck & Co. pays Cardiome milestone after filing for European approval for vernakalant

Etravirine treatment shows safety and efficacy in HIV patients; pooled phase III data disclosed

VIR-201 vaccine partially suppresses HIV replication in phase I/IIa clinical trial

PET tracer BAY-94-9172 shown promise as diagnostic agent for AD in phase II trials

GlaxoSmithKline and Genmab report top-line results for ofatumumab in RA

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...